Inspire Medical Systems (NYSE:INSP) Price Target Cut to $220.00 by Analysts at Morgan Stanley

Inspire Medical Systems (NYSE:INSP) had its price target cut by Morgan Stanley from $230.00 to $220.00 in a research note published on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

Several other research analysts have also recently issued reports on the company. Royal Bank of Canada reissued an “outperform” rating and issued a $260.00 price objective on shares of Inspire Medical Systems in a research note on Tuesday, November 5th. Wells Fargo & Company dropped their price target on Inspire Medical Systems from $198.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Stifel Nicolaus decreased their price objective on Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating for the company in a report on Tuesday, January 21st. Piper Sandler dropped their target price on shares of Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating on the stock in a report on Monday. Finally, KeyCorp restated an “overweight” rating and issued a $234.00 price target (down previously from $236.00) on shares of Inspire Medical Systems in a report on Friday, January 24th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $228.82.

Inspire Medical Systems Trading Up 1.2 %

NYSE:INSP opened at $183.17 on Tuesday. The company has a market cap of $5.49 billion, a price-to-earnings ratio of 171.18 and a beta of 1.32. Inspire Medical Systems has a twelve month low of $123.00 and a twelve month high of $257.40. The stock has a fifty day simple moving average of $189.57 and a 200-day simple moving average of $190.98.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, February 10th. The company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%. As a group, equities research analysts predict that Inspire Medical Systems will post 1.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Inspire Medical Systems

Institutional investors have recently bought and sold shares of the company. Mutual of America Capital Management LLC increased its position in shares of Inspire Medical Systems by 1.2% during the fourth quarter. Mutual of America Capital Management LLC now owns 4,540 shares of the company’s stock worth $842,000 after purchasing an additional 55 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Inspire Medical Systems by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 7,879 shares of the company’s stock valued at $1,461,000 after buying an additional 79 shares in the last quarter. Xponance Inc. raised its stake in Inspire Medical Systems by 2.2% in the fourth quarter. Xponance Inc. now owns 3,824 shares of the company’s stock valued at $709,000 after buying an additional 82 shares during the last quarter. Signaturefd LLC boosted its holdings in Inspire Medical Systems by 45.9% in the third quarter. Signaturefd LLC now owns 270 shares of the company’s stock worth $57,000 after acquiring an additional 85 shares in the last quarter. Finally, Harbour Investments Inc. grew its stake in shares of Inspire Medical Systems by 101.0% during the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock worth $37,000 after acquiring an additional 99 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.